Clinical Trial of a PreS2-containing Recombinant Hepatitis B Vaccine View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

1994

AUTHORS

Yoshihiro Akahane

ABSTRACT

Conventional hepatitis B vaccines have met with three problems: escape mutants, delayed anti-HBs response, and nonresponders. We conducted a clinical trial of a preS2-containing hepatitis B vaccine in a ‘virgin group’ (previously neither vaccinated nor infected) and in ‘nonresponders’ (previously vaccinated at least thrice), and concluded that this vaccine could overcome 2 of the 3 usual vaccine problems. The virgin group vaccinees showed a faster and more complete seroconversion to anti-preS2 than to anti-HBs, with 100% anti-preS2 positive by 7 months after the initial vaccine. The anti-preS2 antibody titer began to rise at month 1, and peaked at month 2, while the anti-HBs antibody titer showed a later, gradual increase. About 60% of the nonresponders became positive for anti-preS2, anti-HBs, or both after a single shot of the vaccine, and 80% after the second shot. More... »

PAGES

533-535

Book

TITLE

Viral Hepatitis and Liver Disease

ISBN

978-4-431-68257-8
978-4-431-68255-4

Author Affiliations

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-4-431-68255-4_139

DOI

http://dx.doi.org/10.1007/978-4-431-68255-4_139

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1009463307


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Yamanashi", 
          "id": "https://www.grid.ac/institutes/grid.267500.6", 
          "name": [
            "Yamanashi Medical University, Shimokato 1110, Tamaho-cho, Nakakoma-gun, Yamanashi-ken\u00a0409-38, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Akahane", 
        "givenName": "Yoshihiro", 
        "id": "sg:person.0577560003.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577560003.48"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1203/00006450-199209000-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014179279", 
          "https://doi.org/10.1203/00006450-199209000-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.83.23.9174", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028096136"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0264-410x(90)90044-m", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032926671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0264-410x(90)90044-m", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032926671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.82.23.8168", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044141951"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0140-6736(90)91874-a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051250904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0140-6736(90)91874-a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051250904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.2408336", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062536354"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1994", 
    "datePublishedReg": "1994-01-01", 
    "description": "Conventional hepatitis B vaccines have met with three problems: escape mutants, delayed anti-HBs response, and nonresponders. We conducted a clinical trial of a preS2-containing hepatitis B vaccine in a \u2018virgin group\u2019 (previously neither vaccinated nor infected) and in \u2018nonresponders\u2019 (previously vaccinated at least thrice), and concluded that this vaccine could overcome 2 of the 3 usual vaccine problems. The virgin group vaccinees showed a faster and more complete seroconversion to anti-preS2 than to anti-HBs, with 100% anti-preS2 positive by 7 months after the initial vaccine. The anti-preS2 antibody titer began to rise at month 1, and peaked at month 2, while the anti-HBs antibody titer showed a later, gradual increase. About 60% of the nonresponders became positive for anti-preS2, anti-HBs, or both after a single shot of the vaccine, and 80% after the second shot.", 
    "editor": [
      {
        "familyName": "Nishioka", 
        "givenName": "K.", 
        "type": "Person"
      }, 
      {
        "familyName": "Suzuki", 
        "givenName": "H.", 
        "type": "Person"
      }, 
      {
        "familyName": "Mishiro", 
        "givenName": "S.", 
        "type": "Person"
      }, 
      {
        "familyName": "Oda", 
        "givenName": "T.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-4-431-68255-4_139", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-4-431-68257-8", 
        "978-4-431-68255-4"
      ], 
      "name": "Viral Hepatitis and Liver Disease", 
      "type": "Book"
    }, 
    "name": "Clinical Trial of a PreS2-containing Recombinant Hepatitis B Vaccine", 
    "pagination": "533-535", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-4-431-68255-4_139"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2d1438f5268c665c9a2855cd1ab675ec9d041e19d101eae0b16909b87f2363e7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1009463307"
        ]
      }
    ], 
    "publisher": {
      "location": "Tokyo", 
      "name": "Springer Japan", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-4-431-68255-4_139", 
      "https://app.dimensions.ai/details/publication/pub.1009463307"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2019-04-15T11:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000248.jsonl", 
    "type": "Chapter", 
    "url": "http://link.springer.com/10.1007/978-4-431-68255-4_139"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-68255-4_139'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-68255-4_139'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-68255-4_139'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-68255-4_139'


 

This table displays all metadata directly associated to this object as RDF triples.

99 TRIPLES      23 PREDICATES      33 URIs      20 LITERALS      8 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-4-431-68255-4_139 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author Nf9da296fcbbb419885aed07c2a553f1c
4 schema:citation sg:pub.10.1203/00006450-199209000-00002
5 https://doi.org/10.1016/0140-6736(90)91874-a
6 https://doi.org/10.1016/0264-410x(90)90044-m
7 https://doi.org/10.1073/pnas.82.23.8168
8 https://doi.org/10.1073/pnas.83.23.9174
9 https://doi.org/10.1126/science.2408336
10 schema:datePublished 1994
11 schema:datePublishedReg 1994-01-01
12 schema:description Conventional hepatitis B vaccines have met with three problems: escape mutants, delayed anti-HBs response, and nonresponders. We conducted a clinical trial of a preS2-containing hepatitis B vaccine in a ‘virgin group’ (previously neither vaccinated nor infected) and in ‘nonresponders’ (previously vaccinated at least thrice), and concluded that this vaccine could overcome 2 of the 3 usual vaccine problems. The virgin group vaccinees showed a faster and more complete seroconversion to anti-preS2 than to anti-HBs, with 100% anti-preS2 positive by 7 months after the initial vaccine. The anti-preS2 antibody titer began to rise at month 1, and peaked at month 2, while the anti-HBs antibody titer showed a later, gradual increase. About 60% of the nonresponders became positive for anti-preS2, anti-HBs, or both after a single shot of the vaccine, and 80% after the second shot.
13 schema:editor N42148ab1a9bb4fb18093276d22904cd3
14 schema:genre chapter
15 schema:inLanguage en
16 schema:isAccessibleForFree false
17 schema:isPartOf N6af8491f1b3f404183cd016df6308788
18 schema:name Clinical Trial of a PreS2-containing Recombinant Hepatitis B Vaccine
19 schema:pagination 533-535
20 schema:productId N7c67dd22eca54875a35c93ef0b188c76
21 Nb0bd5e676b4b4d9d95bfa7d3faa04bcb
22 Nd2827e0ae2af4b479860ff50c6c5ecd0
23 schema:publisher N5ed54daa8ac344ce80d70551407afbd6
24 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009463307
25 https://doi.org/10.1007/978-4-431-68255-4_139
26 schema:sdDatePublished 2019-04-15T11:32
27 schema:sdLicense https://scigraph.springernature.com/explorer/license/
28 schema:sdPublisher N536f7be3f9c44559933de4c7c02071e6
29 schema:url http://link.springer.com/10.1007/978-4-431-68255-4_139
30 sgo:license sg:explorer/license/
31 sgo:sdDataset chapters
32 rdf:type schema:Chapter
33 N42148ab1a9bb4fb18093276d22904cd3 rdf:first Nab06257827524ecf9b26736803851731
34 rdf:rest N95aee153a4f34ff6b90685b9b6724699
35 N4596f75ff9b74a45a489a49c81e12d52 schema:familyName Oda
36 schema:givenName T.
37 rdf:type schema:Person
38 N536f7be3f9c44559933de4c7c02071e6 schema:name Springer Nature - SN SciGraph project
39 rdf:type schema:Organization
40 N5ed54daa8ac344ce80d70551407afbd6 schema:location Tokyo
41 schema:name Springer Japan
42 rdf:type schema:Organisation
43 N695961f20fcf4f6c807c242628122701 schema:familyName Suzuki
44 schema:givenName H.
45 rdf:type schema:Person
46 N6af8491f1b3f404183cd016df6308788 schema:isbn 978-4-431-68255-4
47 978-4-431-68257-8
48 schema:name Viral Hepatitis and Liver Disease
49 rdf:type schema:Book
50 N7c67dd22eca54875a35c93ef0b188c76 schema:name dimensions_id
51 schema:value pub.1009463307
52 rdf:type schema:PropertyValue
53 N95aee153a4f34ff6b90685b9b6724699 rdf:first N695961f20fcf4f6c807c242628122701
54 rdf:rest Ne01e1a4713d6412cb4810affafee0469
55 N9c272785432448078c7698b898db23d8 rdf:first N4596f75ff9b74a45a489a49c81e12d52
56 rdf:rest rdf:nil
57 Nab06257827524ecf9b26736803851731 schema:familyName Nishioka
58 schema:givenName K.
59 rdf:type schema:Person
60 Nb0bd5e676b4b4d9d95bfa7d3faa04bcb schema:name doi
61 schema:value 10.1007/978-4-431-68255-4_139
62 rdf:type schema:PropertyValue
63 Nd2827e0ae2af4b479860ff50c6c5ecd0 schema:name readcube_id
64 schema:value 2d1438f5268c665c9a2855cd1ab675ec9d041e19d101eae0b16909b87f2363e7
65 rdf:type schema:PropertyValue
66 Nd994182f56c544538320dbeef197c2c5 schema:familyName Mishiro
67 schema:givenName S.
68 rdf:type schema:Person
69 Ne01e1a4713d6412cb4810affafee0469 rdf:first Nd994182f56c544538320dbeef197c2c5
70 rdf:rest N9c272785432448078c7698b898db23d8
71 Nf9da296fcbbb419885aed07c2a553f1c rdf:first sg:person.0577560003.48
72 rdf:rest rdf:nil
73 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
74 schema:name Medical and Health Sciences
75 rdf:type schema:DefinedTerm
76 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
77 schema:name Immunology
78 rdf:type schema:DefinedTerm
79 sg:person.0577560003.48 schema:affiliation https://www.grid.ac/institutes/grid.267500.6
80 schema:familyName Akahane
81 schema:givenName Yoshihiro
82 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577560003.48
83 rdf:type schema:Person
84 sg:pub.10.1203/00006450-199209000-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014179279
85 https://doi.org/10.1203/00006450-199209000-00002
86 rdf:type schema:CreativeWork
87 https://doi.org/10.1016/0140-6736(90)91874-a schema:sameAs https://app.dimensions.ai/details/publication/pub.1051250904
88 rdf:type schema:CreativeWork
89 https://doi.org/10.1016/0264-410x(90)90044-m schema:sameAs https://app.dimensions.ai/details/publication/pub.1032926671
90 rdf:type schema:CreativeWork
91 https://doi.org/10.1073/pnas.82.23.8168 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044141951
92 rdf:type schema:CreativeWork
93 https://doi.org/10.1073/pnas.83.23.9174 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028096136
94 rdf:type schema:CreativeWork
95 https://doi.org/10.1126/science.2408336 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062536354
96 rdf:type schema:CreativeWork
97 https://www.grid.ac/institutes/grid.267500.6 schema:alternateName University of Yamanashi
98 schema:name Yamanashi Medical University, Shimokato 1110, Tamaho-cho, Nakakoma-gun, Yamanashi-ken 409-38, Japan
99 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...